LGALS3BP (Lectin galactoside-binding soluble 3-binding protein)

Furthermore, Gaussian accelerated MD (GaMD) revealed reorganized conformational landscapes together with modest shifts in the underlying free-energy profiles for the engineered antibodies relative to their native scaffolds, in line with the interpretative limits of GaMD reweighting. Collectively, this study positions Gal-3BP as a tractable therapeutic target and presents optimized antibody candidates capable of engaging epitopes minimally affected by glycan shielding, illustrating the potential of integrative computational pipelines for antibody design against structurally complex proteins.

Protein EpiScores are significantly associated with CRC survival. These findings highlight biological pathways underlying CRC prognosis and support the utility of Protein EpiScores for modeling survivorship.

CS/DS content increased 3.4-fold in A549 sEVs, while the ratio of the two monosulfated disaccharides changed 2-fold. These findings demonstrate the utility of N-glycoproteomics and GAG profiling for sensitively characterizing molecular differences between sEVs derived from different cell culture models, thereby providing a foundation for future EV biomarker studies.

Furthermore, high LGALS3BP expression is linked to enhanced sensitivity to chemotherapeutic agents and improved outcomes in immunotherapy. These results highlight LGALS3BP as a potential biomarker for predicting TNBC prognosis and guiding personalized therapeutic strategies.

Siglec-14-positive CRC patients exhibited elevated serum LGALS3BP, which correlated with advanced progression and poorer survival. Collectively, these findings establish the LGALS3BP-Siglec-14 axis as a potential therapeutic target, offering a strategy to enhance antitumor immunity in Siglec-14-positive CRC patients.

Signature proteins in TAM-EVs were characterized, with the identification of galectin-3-binding protein as a signature protein present in EVs from M1-like BMDMs and regressor macrophages. Finally, immunostimulatory pathways were identified in progressor-TAM-EVs through protein-protein interaction network analysis.

A second metastatic model using SKNAS neuroblastoma cells, which endogenously express LGALS3BP, was utilized to study the kinetics of the payload. The approach allows for the simultaneous detection of DM4 and S-methyl-DM4, offering a valuable tool for the comparative assessment of ADC performance in preclinical models.

Furthermore, administration of 1959-sss/DM4 antibody-drug conjugate in two xenograft mouse models of human bladder cancer resulted in complete inhibition of tumor growth. In summary, findings presented here highlight LGALS3BP as a promising candidate for further investigation into its potential as a urinary biomarker and a therapeutic target for bladder cancer.

An 18-protein (PURB, SDCBP2, CD2BP2, GALM, SERPINA3, OAS3, FAN1, ZPR1, KRT2, NUDT2, SMNDC1, SERPINA4, CUTA, WDR36, POSTN, CLEC11A, PEX14, and PI4KA) risk score demonstrated independent prognostic significance for overall survival, and recurrence, and was validated in an independent proteomic dataset generated using a different proteomic technology. This study introduces four novel prognostic PDA subtypes and an 18-protein risk score, validated in an independent dataset, which show promise for improving survival prediction and could serve as a valuable tool for personalized treatment guidance.

Of the ten putative diagnostic biomarkers, extracellular vesicle-associated miR-21-3p, miR-26a-5p, miR-130a-3p, miR-139 and miR-219a-5p are the most promising as their expression in extracellular vesicle preparations appears to reflect that in endometrial tissue. However, there are significant concerns regarding study quality, limited adherence to consensus recommendations on extracellular vesicle research and lack of evidence supporting biomarkers being encapsulated within extracellular vesicles.